Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

On Friday, Novo Nordisk A/S NVO released headline results from the REDEFINE 1 Phase 3 trial in the global REDEFINE program.

What's Going On With Amgen Stock On Friday?

Caterpillar

Salesforce

Chevron

Goldman Sachs

Home Depot

NVIDIA

Sherwin-Williams

Travelers

UnitedHealth Group

Investors seemed to shrug off the meltdown on Thursday. Some Dow Jones laggards of this period tried to rebound as well.

10 Biggest Losers of The Dow Jones Index's 10-Day Losing Streak

Johnson & Johnson

Merck

The Dow Jones industrial average is a price-weighted index of 30 blue-chip U.S.

Dow Losing Streak Longest in 50 Years: Grab These Bargain Blue-Chip Dividend Stocks Now

Biomotion Sciences

LONDON--(BUSINESS WIRE)---- $AMGN #biotech--PESG Research Releases an Market Update Report on Silexion Therapeutics (NASDAQ: SLXN). The precision oncology sector has rapidly evolved into one of the most dynamic areas of cancer treatment innovation. Among the key players pioneering novel approaches is Silexion Therapeutics, a clinical-stage biotechnology company focused on RNA interference (RNAi) therapies for KRAS-driven cancers—one of the most prevalent and historically “undruggable” oncogenic drivers. Silexion'.

PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises

Verizon

The Dow Jones is one of Wall Street's most iconic benchmarks and it tracks 30 of America's largest companies.

Should You Buy the 3 Highest Yielding Dividend Stocks in the Dow Jones?

Apple

AbbVie

Abbott Labs

Accenture Plc

Adobe

Automatic Data Processing

Amazon

Air Products and Chemicals

Broadcom

Boeing

Booking Hlds

Colgate-Palmolive

Comcast

Chipotle

ConocoPhillips

Costco

Cisco Systems

Corteva Inc

DuPont de Nemours

Deere & Company

Danaher

Concentrate on a select few high-conviction stocks across different sectors to avoid "diworsification" and maximize returns, inspired by Charlie Munger and Warren Buffett. Utilize Joel Greenblatt's "Magic Formula" and James O'Shaughnessy's methodologies to screen stocks based on earnings yield and return on total capital. Exclude overly regulated sectors like Utilities, Financials, and REITs to focus on sectors with higher growth potential and less regulatory constraints.

Best Way To Invest $100,000: Build An 8-Stock Portfolio For Growth And Value

NIKE

It's been a banner year for the stock market. However, not every stock has been a winner as some sectors performed better than others.

These Are the 5 Worst-Performing Stocks in the Dow Jones Industrial Average With 2024 Almost Over

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Amgen (AMGN) is a Top Growth Stock for the Long-Term

Amgen (AMGN) reachead $273.41 at the closing of the latest trading day, reflecting a -0.85% change compared to its last close.

Amgen (AMGN) Stock Sinks As Market Gains: Here's Why

THOUSAND OAKS, Calif. , Dec. 10, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the first quarter of 2025.

AMGEN ANNOUNCES 2025 FIRST QUARTER DIVIDEND

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Amgen (AMGN) is a Strong Value Stock

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock

Coca-Cola

Whether you're looking for a way to beat the benchmark S&P 500 index or you just want a steady flow of passive income, dividend-paying stocks are a great way to achieve your investment goals.

2 No-Brainer Dividend Stocks With Yields Over 3% to Buy in 2025 and Hold for a Decade or Longer

It's time to take a look at the "Dogs of the Dow." Are the highest-yielding stocks of the Dow Jones Industrial Average (^DJI -0.28%) index undervalued, fantastic buys -- or did their prices fall and dividend yields soar for scary reasons?

Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?

Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse.

BLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)

Wall Street is chewing over data on Amgen's weight loss injection, MariTde. Meanwhile, GE HealthCare will acquire a Japanese drug company.

Healthy Returns: Wall Street mulls over Amgen's weight loss drug data

U.S. drugmaker Amgen said on Thursday it will invest $1 billion towards a second drug substance manufacturing facility in North Carolina.

Amgen to invest $1 bln in North Carolina manufacturing site

Investment Establishes Second Facility in Holly Springs; Builds on Previous $550M Commitment THOUSAND OAKS, Calif. , Dec. 5, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $1 billion expansion to establish a second drug substance manufacturing facility in North Carolina.

AMGEN ANNOUNCES $1 BILLION MANUFACTURING EXPANSION IN NORTH CAROLINA

The relationship between interest rates and dividend stocks tends to follow a predictable pattern. When the Federal Reserve signals a shift toward monetary easing, investors often rotate toward stable, high-yielding equities that can provide both income and potential appreciation.

Is Amgen Still a Top Dividend Stock?

Disney

JPMorgan Chase & Co

McDonald's

Microsoft

Procter & Gamble

Verizon is the only Dow Dog meeting the ideal of annual dividends from $1K invested exceeding its single share price. Five more Dow Dogs, including Cisco and Merck, are within 66% of meeting this ideal. Analysts forecast 11.36% to 31.73% net gains from top-ten Dow Dogs by December 2025, with Merck leading at 31.73%.

Dow 30 December Dogs Show 28 Pay Dividends And 1 "Safer" Buy

Amgen Inc. (NASDAQ:AMGN ) Annual Evercore ISI HealthCONx Healthcare Conference December 4, 2024 10:00 AM ET Company Participants Peter Griffith - Executive Vice President and Chief Financial Officer James Bradner - Executive Vice President, Research and Development, and Chief Scientific Officer Susan Sweeney - Executive Vice President, Obesity and Related Conditions Justin Claeys - Vice President, Investor Relations Conference Call Participants Umer Raffat - Evercore ISI Umer Raffat Excellent. Hello, everyone.

Amgen Inc. (AMGN) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)

AMGN's reasonable valuation, an interesting pipeline and continued top-line growth are good enough reasons to stay invested in the stock for now.

Amgen Stock Falls 12% in a Month: Should You Buy the Dip?

Eli Lilly

The battle for the multibillion-dollar obesity market just got fiercer. Amgen Inc's AMGN new drug candidate, MariTide, reported promising results, helping patients shed around 20% of their body weight.

Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance

MPLX

With markets surging, finding high-yield bargains can feel impossible. Yet, opportunities still exist for disciplined, value-focused investors. My strategy targets strong, dividend-paying businesses trading below their true worth. These picks combine yield, growth, and resilience. By focusing on fundamentals and long-term potential, I've identified two standout stocks. They're not just high-yield, they're future-proof investments.

Bargain Hunting In A Pricey Market: 2 High-Yield Dividend Picks That Have Me Hooked

THOUSAND OAKS, Calif. , Dec. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2024 Global Healthcare Conference at 9:30 a.m.

News for Amgen Stock (AMGN)